New medicine to treat MRSA gets FDA approval.

The Washington Post (6/3, Bernstein) “To Your Health” blog reports that the FDA recently gave the green light to “a new drug to combat acute skin and soft tissue infections, including methicillin-resistant Staphylococcus aureus, or MRSA.” The drug, known as Dalvance, “is the first approved by the FDA under the government’s Generating Antibiotic Incentives program.”

        CNN (6/4, Christensen) reported that Dalavance, an intravenous medicine, is made by Durata Therapeutics and is approved for adults only. CNN noted that Dalvance received approval “after two clinical trials that included 1,289 adults with this kind of infection.” Participants in the study received either Dalvance or another antibacterial medicine. “Dalvance was as effective as that drug for the treatment of this infection,” CNN reported.